iShares S&P 500 ETF

IVV

IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

AUB Group Limited

AUB

AUB Group Ltd. engages in the provision of equity-based insurance broker network. The company is headquartered in Sydney, New South Wales and currently employs 2,582 full-time employees. The company went IPO on 2005-11-16. Its segments include Australian Broking, Agencies, New Zealand Broking, International, and Support Services. Australian Broking and New Zealand Broking businesses provide insurance broking and advisory services primarily to small to medium-sized enterprise clients. The division encompasses broking businesses, complemented by capabilities in member services, life insurance broking, and claims management. Agencies distribute and manage insurance products on behalf of licensed insurance companies through general commercial, strata and specialty sub-divisions through underwriting agencies with access to underwriting capacity. International includes Tysers/International includes Wholesale and retail broking and managing general agents. Support service businesses provide a diverse range of services to support the Australian Broking, Agencies, New Zealand Broking and Tysers segments, and external clients.

Botanix Pharmaceuticals Ltd

BOT

Botanix Pharmaceuticals Ltd. is a dermatology company, which engages in the provision of business of researching and developing dermatology and antimicrobial products. The company is headquartered in Perth, Western Australia. The Company’s lead product is Sofdra (sofpironium) topical gel, 12.45%, a prescription anticholinergic medicine used on the skin (topical), to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children nine years of age and older. Sofdra regulates sweating at the site of application, by binding to the primary sweat receptor and thereby blocking the sweat signal. Its product pipeline targets the various skin diseases, such as BTX 1503 for Acne, BTX 1702 for Rosacea, BTX 1204A for Atopic Dermatitis, and BTX 1801 for Hemodialysis Patients. Its BTX 1503 is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. BTX 1702 is used for the treatment of papulopustular rosacea. BTX 1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA).

Change Financial Limited

CCA

Change Financial Ltd. engages in the provision of mobile digital banking. The company is headquartered in Brisbane, Queensland. The company went IPO on 2016-06-30. The firm leverages scalable technology to provide payment solutions, card issuing and testing to banks and fintechs. Its principal activity includes commercialization and ongoing development of its payments management platform and payment testing solution. Its core products include Vertexon Payments as a Service (PaaS) and PaySim. Vertexon (PaaS) integrates with the core systems of banks and fintechs, enabling the delivery of physical, digital, and virtual card solutions to their customers. The company includes integrated features such as Apple Pay, Google Pay, Samsung Pay and Buy Now Pay Later (BNPL) services. PaySim is a payment testing solution, which enables banks and fintechs to complete end-to-end testing of their payment platforms and processes from a desktop. The company also provides the default standard for payments testing for many Australian companies, including Australia’s domestic card payment service EFTPO.

SPDR S&P/ASX 200 ETF

STW

STW.AX was created on 2001-08-24 by SPDR. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 5823.98m in AUM and 201 holdings. The SPDR S&P/ASX 200 ETF, seeks to closely match, before fees and expenses, the returns of the S&P/ASX 200 Index.